Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors

Summary

This phase I trial studies the side effects and best dose of ribociclib and everolimus and to see how well they work in treating patients with malignant brain tumors that have come back or do not respond to treatment. Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as everolimus, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ribociclib and everolimus may work better at treating malignant brain tumors.

Timeline

Start

2018-01-13

Primary completion

2020-04-01

Completion

2020-04-01

Drugs

Indications